Cabozantinib (Cabometyx®, Cometriq®): A 2025 Clinical Overview
Cabozantinib is an oral tyrosine kinase inhibitor (TKI) used in the treatment of several advanced and metastatic cancers. It inhibits multiple pathways involved in tumor growth, angiogenesis, and metastasis, making…